Article info
PDFClinical and epidemiological research
Extended report
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials
- Correspondence to Dr Ryan DeMasi; Pfizer Inc, 235 E 42nd St, New York, NY 10017, USA; Ryan.DeMasi{at}pfizer.com
Citation
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials
Publication history
- Received September 2, 2016
- Revised December 8, 2016
- Accepted December 26, 2016
- First published January 31, 2017.
Online issue publication
June 12, 2017
Article Versions
- Previous version (31 January 2017).
- You are viewing the most recent version of this article.
Lay summary
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/